Stokes Family Office LLC Acquires 1,840 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Stokes Family Office LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 36.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,934 shares of the medical research company’s stock after purchasing an additional 1,840 shares during the period. Stokes Family Office LLC’s holdings in Charles River Laboratories International were worth $1,879,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of CRL. VisionPoint Advisory Group LLC boosted its holdings in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after buying an additional 74 shares during the period. Brown Brothers Harriman & Co. boosted its stake in Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC bought a new position in Charles River Laboratories International during the 4th quarter worth about $62,000. Bruce G. Allen Investments LLC acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at about $70,000. Finally, Concord Wealth Partners lifted its holdings in shares of Charles River Laboratories International by 362.5% in the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 203 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

CRL has been the subject of a number of research reports. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, June 14th. TD Cowen lowered their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a report on Monday, May 13th. The Goldman Sachs Group began coverage on shares of Charles River Laboratories International in a research report on Thursday, June 6th. They issued a “buy” rating and a $290.00 price objective on the stock. Barclays initiated coverage on shares of Charles River Laboratories International in a research report on Friday, June 28th. They issued an “equal weight” rating and a $230.00 target price for the company. Finally, Mizuho assumed coverage on shares of Charles River Laboratories International in a research report on Friday, June 7th. They set a “neutral” rating and a $235.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $252.29.

Charles River Laboratories International Stock Performance

Shares of CRL traded up $5.34 during mid-day trading on Friday, reaching $216.22. The company’s stock had a trading volume of 531,826 shares, compared to its average volume of 536,149. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The business has a 50-day simple moving average of $214.47 and a two-hundred day simple moving average of $230.74. The stock has a market cap of $11.14 billion, a P/E ratio of 25.44, a PEG ratio of 1.92 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).